^
Contact us  to learn more about
our Premium Content:  News alerts, weekly reports and conference planners
DRUG CLASS:

eIF4G1 inhibitor

over2years
Targeting eIF4F translation complex sensitizes B-ALL cells to tyrosine kinase inhibition. (PubMed, Sci Rep)
SBI-756, a small molecule inhibitor of eIF4F assembly, sensitizes human Ph+ and Ph-like B-ALL cells to dasatinib cytotoxicity without affecting survival of T lymphocytes or natural killer cells. These findings support the further evaluation of eIF4F-targeted molecules in combination therapies with TKIs in B-ALL and other blood cancers.
Journal
|
EIF4G1 (Eukaryotic translation initiation factor 4 gamma, 1)
|
dasatinib • SBI-756